Eiko Lifesciences Ltd — Important, 11-12-2025: Company Update

Eiko LifeSciences' board approved a strategic acquisition of 51% equity in SSM Formulations, a pharmaceutical manufacturer, for 18 Cr. This move aims to diversify Eiko's product portfolio and integrate forward into pharma formulations. SSM Formulations recorded turnovers of 27.65 Cr (FY25), 41.41 Cr (FY24), and 50.82 Cr (FY23). Additionally, the board approved raising up to 18.15 Cr through issuing 33 lakh warrants and up to 3.71 Cr via 6.75 lakh equity shares, both at Rs. 55 each on a preferential basis. The company has announced an Extra Ordinary General Meeting on January 07, 2026, to seek shareholder approval for these fund-raising initiatives.